MIST vs MLTX

Milestone Pharmaceuticals Inc. vs MoonLake Immunotherapeutics — Valuation Comparison 2026

MIST

Biotechnology
Milestone Pharmaceuticals Inc.
Quality
3.6
out of 10
Value Trap
30
LOW
Price
$1.44
Last close
Models
7/13
Active
VS

MLTX

Biotechnology
MoonLake Immunotherapeutics
Quality
4.0
out of 10
Value Trap
30
LOW
Price
$18.68
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType MIST Fair ValueMIST Upside MLTX Fair ValueMLTX Upside
Bayesian DCF Intrinsic $0.50 -65.3% $6.65 -64.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.45 -97.3%
Dynamic NAV Asset-Based $0.23 -83.7% $4.61 -75.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MIST vs MLTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MIST vs MLTX — Which Stock Is More Undervalued?

MLTX scores higher with a 4.0/10 quality rating vs MIST's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Milestone Pharmaceuticals Inc. (MIST) and MoonLake Immunotherapeutics (MLTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MIST currently trades at $1.44 with a QOC of 3.6/10, while MLTX trades at $18.68 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).